Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
combination therapy
Pharma
Despite trial miss, Bausch + Lomb advances combo to ph. 3
Bausch + Lomb has flunked a phase 2 trial of its combination of dry-eye disease drugs Xiidra and Miebo, but will advance the combo to phase 3.
Kevin Dunleavy
Aug 25, 2026 10:46am
Kelun's sac-TMT win offers blueprint for Merck's global gap
Jul 15, 2026 10:20am
FDA expands Padcev-Keytruda combo to more MIBC patients
Jul 10, 2026 1:10pm
Verastem mulls options on approved asset in pancreatic cancer
Jun 17, 2026 3:00pm
Lilly oncology chief ‘blown away’ by new Jaypirca CLL data
Jun 15, 2026 8:25am
ASCO: Incyte positions Monjuvi combo for first-line DLBCL
May 30, 2026 8:00am
